Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Genetics

Open Access

Association of ADIPOQ gene with type 2 diabetes and related phenotypes in African American men and women: the Jackson Heart Study

  • Sharon K. Davis1Email author,
  • Ruihua Xu1,
  • Samson Y. Gebreab1,
  • Pia Riestra1,
  • Amadou Gaye1,
  • Rumana J. Khan1,
  • James G. Wilson2 and
  • Aurelian Bidulescu3
BMC Genetics201516:147

https://doi.org/10.1186/s12863-015-0319-4

Received: 29 September 2015

Accepted: 14 December 2015

Published: 23 December 2015

Abstract

Background

African Americans experience disproportionately higher prevalence of type 2 diabetes and related risk factors. Little research has been done on the association of ADIPOQ gene on type 2 diabetes, plasma adiponectin, blood glucose, HOMA-IR and body mass index (BMI) in African Americans. The objective of our research was to assess such associations with selected SNPs. The study included a sample of 3,020 men and women from the Jackson Heart Study who had ADIPOQ genotyping information. Unadjusted and adjusted regression models with covariates were used with type 2 diabetes and related phenotypes as the outcome stratified by sex.

Results

There was no association between selected ADIPOQ SNPs with type 2 diabetes, blood glucose, or BMI in men or women. There was a significant association between variant rs16861205 and lower adiponectin in women with minor allele A in the fully adjusted model (β(SE) p = −.13(0.05), 0.003). There was also a significant association with variant rs7627128 and lower HOMA-IR among men with minor allele A in the fully adjusted model (β(SE) p = −0.74(0.20), 0.0002).

Conclusions

These findings represent new insights regarding the association of ADIPOQ gene and type 2 diabetes and related phenotypes in African American men and women.

Keywords

AdiponectinType 2 diabetesADIPOQ geneAfrican Americans

Background

Type 2 diabetes is more prevalent among African Americans when compared to most racial/ethnic groups in the US–even after taking into account socioeconomic status (SES), prevalence and severity of hypertension and access to health care [14]. African Americans also have a higher prevalence of elevated A1C hemoglobin, fasting blood glucose, insulin resistance and obesity which are risk factors for type 2 diabetes [1, 5, 6]. Adverse behavioral lifestyle, such as poor diet and physical inactivity, are contributing factors associated with type 2 diabetes. African Americans have an overall worse lifestyle profile and lower SES [1, 7].

Plasma adiponectin levels are inversely correlated with type 2 diabetes, blood glucose, insulin resistance and obesity [8]. Adiponectin is an adipose tissue-specific hormone that is responsible for increasing energy expenditure and lipid catabolism as well as enhancing fatty acid oxidation and insulin sensitivity [9]. African Americans present with lower levels of adiponectin and have more severe type 2 diabetes phenotypes [10]. The adiponectin gene (ADIPOQ) located at position 3q27 has been established as the main genetic determinant of plasma adiponectin levels with an inheritance genetic component between 30 to 70 % [11]. The ADIPOQ gene spans 1.579 kb and contains 3 exons. The translation start point is located in exon 2 [12]. Several single nucleotide polymorphisms (SNPs) located in ADIPOQ have been associated with adiponectin serum levels, body adiposity and metabolic alterations making this gene a candidate for type 2 diabetes and associated traits [1214]. A limited number of studies have investigated the association of genetic variants in the adiponectin gene with type 2 diabetes and its related phenotypes in African Americans [1519]. Many of these studies have yielded conflicting results due to small sample size, inclusion of only one gender, and the confounding effect of unadjusted population structure and behavioral lifestyle factors. The objective of the current study was to assess the association of SNPs in ADIPOQ with type 2 diabetes, level of plasma adiponectin, blood glucose, insulin resistance and body mass index (BMI) in African American men and women with adjustments for biological, behavioral and socioeconomic factors. We hypothesized that, after adjustments, the variants related with adiponectin would be associated with type 2 diabetes and its related phenotypes.

Research design and Methods

Study subjects

Cross-sectional data from the Jackson Heart Study (JHS) was used in this study. The JHS is a single-site, community-based study of risk factors and causes of heart disease in adult African Americans. A total of 5,301 non-institutionalized African Americans aged 21–95 years residing in three contiguous counties surrounding Jackson, MS were recruited, interviewed and examined by certified technicians according to standardized protocols at baseline from 2000–2004 [20, 21]. All of the participants gave written informed consent to participate. The clinic visits included the collection of data on sociodemographics, anthropometry, survey of medical history, cardiovascular behavioral risk factors and blood and urine for biological risk factors. The data for this study includes a total of 3,020 men and women with complete DNA and total plasma adiponectin conducted on serum specimens collected at baseline from 2000–2004. These 3,020 participants gave consent for genetic analyses and were genotyped separately in the CARe consortium in 2006 using Affymetrix 6.0 platform [22]. This study was approved by the Institutional Review Board of the National Institutes of Health and the study protocol was approved by the Institutional Review Boards of the participating JHS institutions, including the University of Mississippi Medical Center, Jackson State University and Tougaloo College.

Outcome phenotypes

The main outcomes of the study were type 2 diabetes, plasma adiponectin, blood glucose, homeostatis model assessment–insulin resistance (HOMA-IR), and BMI. Type 2 diabetes was defined as fasting plasma glucose ≥ 126 mg/dL or self-reported use of insulin or oral hypoglycemic medications [23]. Adiponectin measurement was derived from venous blood samples drawn from each participant after more than 8 h of fasting. Vials of serum were stored at the JHS central repository in Minneapolis, MN at −80 °C until assayed. Adiponectin concentration was measure as total plasma adiponectin by ELISA system (R & D Systems; Minneapolis, MN). The inter-assay coefficient of variation was 8.8 %. No biological degrading has been described using stored specimens, indicating a high validity for measurement [24]. Fasting plasma glucose and fasting insulin were measured using standard laboratory techniques. The HOMA-IR was calculated as [insulin (microunits per milliliter) x fasting blood glucose (millimoles per liter)]/22.5. Insulin resistance was defined as a HOMA-IR in the highest quartile of its distribution [25]. Body mass index was based on standing height and weight measured on a balance scale in lightweight clothing without shoes or constricting garments with weight recorded to the nearest 0.5 kg and calculated as weight in kilograms by height in meters squared (kg/m2).

Primary predictor: SNP selection genotyping and imputation

A candidate gene approach for the selection of the genetic variants was used. The tagging approach was applied to the entire set of common genetic variants in the ADIPOQ gene (5kb upstream of the first exon and 5kb downstream of the last exon of the gene) with minor allele frequency (MAF) ≥1 % in Yoruba population (YRI) from the International HapMap Project [26]. SNPs were chosen based on their ability to capture genetic information for the YRI population. Tagging SNPs were selected by the Tagger algorithm available through Haploview using a pairwise SNP selection and captured an inter-SNP r2 value of > 0.80 for known polymorphisms in the region. This process resulted in a selection of 15 tagging SNPs for ADIPOQ with a mean r2 of 0.969 of the selected SNPs. This selection captures a high degree (over 95 %) of the known variability in this gene. IMPUTE2 software and reference phased data from the 1000G project were used for genotype imputation to infer ADIPOQ SNPs genotypes [27, 28]. SNP-level quality control metrics were applied prior to downstream analyses and included the following: call rate ≥ 95 %, MAF ≥1 %, Hardy-Weinberg equilibrium (HWE) Bonferroni correction = p ≥ 0.003, and quality measures for imputed SNPs of r2 ≥ 0.3. Of the 15 SNPS, 3 were excluded because they were not available in the JHS data, and an additional 4 were excluded because they that did not meet the HWE criteria-resulting in eight SNPs for subsequent analyses.

Covariates

Information on key covariates, which are known risk factors for type 2 diabetes and related phenotypes, was obtained from baseline examination. Age was derived from self-reported date-of-birth. Proportion of European Ancestry (PEA) for each participant was calculated using HAPMIX supported by the CARe consortium [22, 2931]. The proportion of global European ancestry estimates for the study has a median of 16.0 % and interquartile range of 15 %.

Biological risk factor measures included low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride, C-reactive protein (CRP), plasma leptin, blood glucose, and HOMA-IR. Behavioral risk factors included smoking status, physical activity, BMI, and alcohol consumption. Fasting LDL, HDL, triglyceride and blood glucose were assessed using standard laboratory techniques. Fasting CRP was measured using immunturbidimetric CRP-Latex assay from Kamiya Biomedical Company following manufacturer’s high-sensitivity protocol [32]. The inter-assay coefficients of variation on control samples repeated in each assay were 4.5 and 4.4 % at CRP concentration of 0.45 and 1.56 mg/dL, respectively. The reliability coefficient for masked quality-control replicates was 0.95 for the CRP assay. Fasting leptin was collected via venous blood samples drawn from each participant and analyzed with Human Leptin PIA kit (LINCO Research, St Charles, MI, USA) [33]. Acceptable coefficient of variation was 10 % [33]. Insulin resistance status was estimated with the HOMA as previously described [25]. Smoking status was defined as current smoker and non-smoker. Physical activity was assessed with a physical activity survey instrument comprised of 4 domains (active living, work, home and garden, sport and exercise). A total score was the sum of these domains with a maximum of 24. A higher score indicates a higher level of total physical activity. The calculation of BMI was previously described. Alcohol consumption status was defined as “yes” if participant reported ever consuming alcohol and “no” for those reporting never consuming alcohol. Socioeconomic status (SES) was based on self-reported level of educational attainment - < high school, high school or graduate education equivalency diploma GED), some college or vocational school, bachelors or associate degree, post-college experience.

Statistical analysis

All analyses were stratified by sex because of the differential prevalence of phenotypes. Baseline characteristics of the study sample were conducted by sex using t-test for continuous variables and chi-square for categorical variables. Hardy-Weinberg equilibrium tests for each of the ADIPOQ SNPs were analyzed using chi-square test. We then used logistic regression to assess the association between type 2 diabetes and each ADIPOQ SNP and linear regression was used to examine the associations of each ADIPOQ SNP with plasma, adiponectin, blood glucose, HOMA-IR, and BMI. Six sequential cumulative models, stratified by sex, were fitted for each phenotype with minor allele as the reference. Model 1 included each SNP as the primary predictor (unadjusted), model 2 included age, model 3 included PEA, model 4 included biological risk factors (LDL cholesterol, HDL cholesterol, triglyceride, CRP, plasma leptin), model 5 included behavioral risk factors (smoking status, physical activity, BMI, alcohol consumption), and model 6 included a fully adjusted model with SES based on level of educational attainment. Age, PEA, LDL cholesterol, HDL cholesterol, triglyceride, CRP, plasma leptin, blood glucose, BMI, physical activity and HOMA-IR were entered as continuous variables. Smoking status, alcohol consumption status, and SES were entered as categorical variables. Adiponectin, blood glucose, HOMA-IR and BMI were log transformed to obtain better approximations of the normal distribution prior to analysis. Multiple comparisons were controlled using Bonferroni correction which was defined a priori by dividing the significance level α = 0.05 by the number of selected ADIPOQ SNPS (0.05/8 = 0.00625) [34]. Therefore, a p-value threshold of 0.006 was used to determine statistical significance. Power analyses for the tests of association were computed using the minor allele frequencies and mean values of serum, adiponectin levels from the JHS and the effect sizes originally reported [34]. Assuming a p value of 0.001 and a power of 80 %, we will require 845 subjects per outcome in order to detect a 2 % of variation in adiponectin levels. Analyses were conducted using SAS version 9.3 [35]. Haplotypes were analyzed to identify haplotype blocks using linear regression in PLINK. Haplotypes with an estimated frequency <5 % were excluded from the analysis. Global p-values were obtained by omnibus tests jointly estimating all haplotype effects. Linear and logistic regression analysis was used for the individual haplotype association.

Results

The sex-stratified baseline characteristics of the study population are presented in Table 1. Approximately 38 % of the sample was comprised of men and 62 % women. Women were significantly older and had a lower proportion of European ancestry (p <0.02 and 0.005, respectively). They also had differential levels of education compared to men (p <0.04). Behavioral risk factors were distributed differently between men and women. A higher proportion of men were current smokers, consumed alcohol and were more physically active (p <0.0001 for all). Women had a higher mean BMI (p <0.0001). A differential pattern was also observed regarding biological risk factors. Systolic blood pressure, DBL, LDL cholesterol, and triglyceride were higher among men (p < 0.03, 0.0001, 0.03, 0.0001, 0.0001, respectively). Women had higher HDL cholesterol, plasma adiponectin, leptin, CRP, and HOMA-IR (p < 0.0001, 0.0001, 0.0001, 0.0001, 0.0004, respectively). Additionally, a higher proportion of women had type 2 diabetes and hypertension (p < 0.01 and 0.009, respectively).
Table 1

Characteristics of men and women in the Jackson Heart Study, N = 3020

 

Men

38.15 % (N = 1,152)

Women

61.85 % (N = 1,868)

P-value*

Demographic Factors (N)

   

Age (mean ± std.)

53.96 ± 13.01

55.05 ± 12.73

0.02

PEA (mean ± std.)

0.18 ± 0.09

0.17 ± 0.08 (1283)

0.005

Education, %

38.13 %

61.87 %

 

 <High school

16.74 %

16.60 %

 

 High school + GED±

19.18 %

21.49 %

 

 Some college + vocational school

23.98 %

22.89 %

 

 Bachelors + associate degree

25.02 %

21.28 %

 

 Post-college

15.08 %

17.73 %

0.04

Behavioral Factors (N)

   

 Smoking Status, % Yes

18.05 %

10.99 %

<0.0001

 BMI§ kg/m2 (Mean ± std.)

30.01 ± 6.31

33.26 ± 7.81

<0.0001

 Physical Activity Score (Mean ± std.)

8.55 ± 2.55

8.15 ± 2.58

<0.0001

 Alcohol Consumption, % (N) Yes

59.20 %

40.30 %

<0.0001

Biological Factors (N)

   

 Systolic blood pressure, mmHg

127.8 ± 17.76

126.3 ± 18.34

0.03

 Diastolic blood pressure, mmHg

81.53 ± 10.59

77.46 ± 10.30

<.0001

 Total Cholesterol,

mg/dl (Mean ± std.)

196.6 ± 40.89

199.4 ± 40.36

0.07

 LDL Cholesterol, mg/dl (Mean ± std.)

127.9 ± 37.15

124.8 ± 37.12

0.03

 HDL Cholesterol, mg/dl (Mean ± std.)

45.69 ± 12.79

54.66 ± 14.71

<0.0001

 Fasting Triglyceride Level, mg/dl, (Mean ± std.)

117.7 ± 100.3

101.3 ± 64.46

<0.0001

 Plasma Adiponectin, ug/mL (Mean ± std.)

4.08 ± 3.38

6.04 ± 4.46

<0.0001

 Plasma Leptin, ng/mL (Mean ± std.)

11.81 ± 11.12

38.53 ± 24.80

<0.0001

 Blood Glucose mg/dL (Mean ± std.)

100.9 ± 33.83

100.5 ± 33.80

0.76

 CRP#, mg/dL (Mean ± std.)

0.37 ± 1.13

0.63 ± 0.89

<.0001

 HOMA-IR** (Insulin resistance) (Mean ± std.)

3.49 ± 2.17

3.85 ± 2.56

0.0004

 Type II diabetes, %

17.12 %

20.87 %

0.01

 Hypertension, %

65.55 %

60.84 %

0.009

*Two-sample t-test for continuous variables and chi-square for categorical variables; significance established as

P ≤ 0.05; std standard deviation

PEA Percent European ancestry

± GED Graduate equivalency diploma

BMI Body mass index

§ LDL Low density lipoprotein

HDL High density lipoprotein

CRP C-reactive protein

** HOMA-IR Homeostasis model assessment – insulin resistance

Table 2 shows the characteristics, minor allele frequencies and HWE p-values for the selected ADIPOQ SNPs. Minor allele frequencies ranged from 6 to 43 %. All of the SNPs included in the subsequent analysis conformed to HWE.
Table 2

Characteristics of selected ADIPOQ SNPs in the adiponectin gene

ADIPOQ SNP

Location on chromosome 3*

Gene region

Tagging population

r2┼

Major/Minor allele

MAF

HWE

P-value§

rs16861205

186561634

Intron 1

YRI

0.99357

G/A

0.21245

0.0312

rs12495941

186568180

Intron 1

YRI

0.61244

G/T

0.35333

0.3807

rs7627128

186568799

Intron 1

YRI

0.68362

C/A

0.15217

0.7607

rs9877202

186569607

Intron 1

YRI

0.71281

A/G

0.13273

0.697

rs2036373

186570191

Intron 1

YRI

0.98257

T/G

0.06391

0.9634

rs1501299

186571123

Intron 2

YRI

0.98519

G/T

0.35484

0.5123

rs3821799

186571486

Intron 2

YRI

0.99954

T/C

0.43207

0.1744

rs9842733

186575482

3′-UTR

YRI

0.92664

A/T

0.10153

0.5974

*position based on NCBI Build 36

r2 refers to the measurement of SNPs imputation quality

MAF Major allele frequency

§ HWE Hardy-Weinberg equilibrium; P-value calculated based on chi-square

YRI Yoruba in Ibadan, Nigeria from HAPMAP

Association between ADIPOQ SNPs and phenotypes

Results are presented in Table 3. No ADIPOQ variant was found to be associated with type 2 diabetes in men or women in the crude or adjusted models. Results in Table 4 show no association between any of the variants and plasma adiponectin among men. However, two variants were significantly associated in women. ADIPOQ SNP rs16861205 was significantly associated with adiponectin in women even after adjusting for age, PEA, biological and behavioral risk factors and SES (in fully adjusted model 6: ß (SE) = −0.13(0.05), p = 0.003). ADIPOQ SNP rs1501299 was only significant in the crude model and the one adjusted for age. There were no association with the ADIPOQ SNPs and blood glucose in men or women as indicated in Table 5. Two variants were observed to be significantly associated with HOMA-IR in men. ADIPOQ SNP rs12495941 was significantly associated after adjusting for age, PEA, biological risk factors and behavioral risk factors, but the association attenuated and became marginally non-significant after adjusting for SES (model 6: ß (SE) = 0.40 (0.15), p =0.0086). However, the association between ADIPOQ SNP rs7627128 remained significant even when fully adjusted for SES (model 6: ß (SE) = −0.73 (0.20), p = 0.0003). Table 6 shows one variant was associated with HOMA-IR in women. ADIPOQ SNP rs1501299 was only significant in the crude and age adjusted models (p = 0.003 and 0.003, respectively). Table 7 reveals that there was no association between any of the variants and BMI in men or women.
Table 3

Association between Type 2 diabetes and ADIPOQ SNPs in men and women in the Jackson Heart Study, N = 2,978*

Men, n = 1,133

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

rs16861205

G/A

1.37 (0.89,2.10)

0.1532

1.44 (0.92,2.23)

0.1075

1.93 (1.01,3.53)

0.0322

1.52 (0.78,2.96)

0.2154

1.49 (0.75,2.96)

0.2517

1.51 (0.75,3.06)

0.2502

rs12495941

G/T

0.47 (0.19,1.14)

0.0932

0.52 (0.21,1.29)

0.1560

0.33 (0.11,0.99)

0.0489

0.54 (0.09,3.45)

0.5182

0.54 (0.08,3.51)

0.5149

0.42 (0.06,2.97)

0.3833

rs7627128

C/A

0.82 (0.19,3.52)

0.7895

1.06 (0.24,4.75)

0.9434

3.18 (0.18,56.0)

0.4301

8.35 (0.18,442)

0.2696

11.01 (0.19,621)

0.2413

12.55 (0.21,737)

0.2234

rs9877202

A/G

0.97 (0.61,1.54)

0.8969

0.96 (0.60,1.54)

0.8642

0.95 (0.54,1.68)

0.8648

0.98 (0.50,1.90)

0.9477

0.80 (0.40,1.60)

0.5230

0.82 (0.41,1.66)

0.5828

rs2036373

T/G

0.20 (0.01,5.07)

0.3303

0.13 (0.01,3.63)

0.2304

0.03 (<0.001,1.4)

0.0727

0.025 (<0.001, 1.12)

0.0571

0.015 (<0.001,0.79)

0.0376

0.018 (<0.001,0.964

0.0479

rs1501299

G/T

1.09 (0.66,1.82)

0.7310

1.10 (0.66,1.86)

0.7111

0.93 (0.49,1.76)

0.8240

0.73 (0.36,1.45)

0.3658

0.68 (0.34,1.39)

0.2913

0.71 (0.35,1.45)

0.3413

rs3821799

T/C

1.06 (0.77,1.44)

0.7308

1.02 (0.75,1.41)

0.8814

1.01 (0.72,1.62)

0.7151

1.00 (0.62,1.61)

0.9976

1.02 (0.62,1.69)

0.9313

0.96 (0.57,1.61)

0.8762

rs9842733

A/T

3.96 (0.43,36)

0.2224

4.40 (0.44,43.89)

0.2073

26.62 (0.174,>999)

0.2009

775 (0.009,>999)

0.2526

739 (0.008,>999)

0.2571

344 (0.008,>999)

0.2835

Women, n = 1,845

SNPs

Alleles

Model 1┼

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

rs16861205

G/A

1.12 (0.80,1.57)

0.5021

1.15 (0.85,1.56)

0.3648

1.15 (0.78,1.68)

0.4872

1.21 (0.77,1.89)

0.4096

1.13 (0.70,1.81)

0.6175

1.17 (0.72,1.89)

0.5274

rs12495941

G/T

1.03 (0.54,1.97)

0.9361

1.15 (0.60,2.21)

0.6819

1.89 (0.58,6.17)

0.2909

2.85 (0.52,15.5)

0.2259

2.62 (0.47,14.5)

0.2703

3.15 (0.56,17.75)

0.1935

rs7627128

C/A

0.57 (0.20,1.66)

0.2993

0.73 (0.24,2.20)

0.5756

0.67 (0.14,3.17)

0.6127

1.58 (0.16,15.7)

0.6985

1.05 (0.10,11.1)

0.9705

1.07 (0.10,11.93)

0.9562

rs9877202

A/G

0.83 (0.61,1.15)

0.2601

0.81 (0.59,1.12)

0.1989

0.91 (0.59,1.40)

0.6607

0.94 (0.55,1.58)

0.8034

1.05 (0.58,1.88)

0.8847

1.04 (0.58,1.88)

0.8863

rs2036373

T/G

2.56 (0.09,75)

0.5870

1.56 (0.05,51)

0.8028

0.95 (0.03,28)

0.9781

2.48 (0.02,255)

0.7004

1.10 (0.01,140)

0.9685

1.17 (0.01,141)

0.9484

rs1501299

G/T

1.50 (0.97,2.30)

0.0718

1.41 (0.91,2.2)

0.1237

1.33 (0.78,2.28)

0.2949

1.44 (0.75,2.76)

0.2766

2.34 (1.08, 5.06)

0.0309

2.46 (1.13, 5.36)

0.0232

rs3821799

T/C

0.93 (0.75,1.17)

0.5489

0.93 (0.74,1.17)

0.5445

0.84 (0.63,1.12)

0.2347

0.85 (0.60,1.19)

0.3359

0.83 (0.57,1.19)

0.3074

0.82 (0.57,1.19)

0.3018

rs9842733

A/T

0.71 (0.30,1.67)

0.4362

0.85 (0.36,2.04)

0.7187

0.76 (0.26,2.17)

0.6019

0.78 (0.23,2.62)

0.6816

0.58 (0.15,2.26)

0.4308

0.59 (0.15,2.33)

0.4529

* N represents 42 missing values for type 2 diabetes

Model 1: crude

Model 2: adjusted for age

§Model 3: adjusted for age, PEA

Model 4: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin

Model 5: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, smoking status, physical activity score, BMI, alcohol consumption status

#Model 6: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin,, smoking status, physical activity score, BMI, alcohol consumption status, socioeconomic status (education level)

Two-tailed level of significance was established as P ≤ 0.006

Table 4

Association between plasma adiponectin level and ADIPOQ SNPs among men and women in the Jackson Heart Study, N = 2,968*

Men, n = 1,131

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

−0.10(0.05)

0.0578

−0.09(0.05)

0.0652

−0.14(0.06)

0.0124

−0.09(0.05)

0.1075

−0.10(0.06)

0.0603

−0.10(0.06)

0.0914

rs12495941

G/T

−0.12(0.14)

0.3822

−0.08(0.14)

0.5438

−0.12(0.16)

0.4513

0.04(0.17)

0.8283

−0.01(0.18)

0.9377

−0.03(0.18)

0.8546

rs7627128

C/A

−0.19(0.20)

0.3345

−0.12(0.19)

0.5436

−0.13(0.26)

0.6145

−0.25(0.24)

0.2962

−0.30(0.24)

0.2086

−0.31(0.24)

0.1968

rs9877202

A/G

−0.08(0.06)

0.1709

−0.08(0.06)

0.1652

−0.10(0.06)

0.1192

−0.06(0.06)

0.3117

−0.09(0.06)

0.1764

−0.10(0.07)

0.1207

rs2036373

T/G

−1.12(0.52)

0.0335

−1.16(0.51)

0.0240

−0.92(0.57)

0.1080

−0.14(0.56)

0.7934

−0.47(0.60)

0.4295

−0.52(0.59)

0.3827

rs1501299

G/T

−0.01(0.06)

0.9324

−0.01(0.06)

0.8870

−0.06(0.07)

0.410

−0.12(0.06)

0.0719

−0.13(0.07)

0.0533

−0.14(0.07)

0.0491

rs3821799

T/C

0.04(0.04)

0.3710

0.03(0.04)

0.4916

0.02(0.04)

0.6712

0.007(0.04)

0.8744

−0.01(0.04)

0.9014

−0.01(0.04)

0.8580

rs9842733

A/T

−0.17(0.20)

0.3862

−0.19(0.19)

0.3223

−0.33(0.22)

0.1436

−0.20(0.20)

0.3165

−0.32(0.24)

0.1378

−0.33(0.21)

0.1284

Women, n = 1,837

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

−0.14(0.04)

0.0001

−0.14(0.04)

0.0002

−0.11(0.04)

0.0089

−0.10(0.04)

0.017

−0.13(0.05)

0.006

−0.13(0.05)

0.003

rs12495941

G/T

0.09(0.08)

0.3047

0.12(0.08)

0.1551

0.008(0.12)

0.9416

0.06(0.10)

0.5292

0.07(0.11)

0.5227

0.07(0.11)

0.5428

rs7627128

C/A

−0.06(0.15)

0.6956

−0.01(0.15)

0.9514

−0.15(0.20)

0.4585

−0.32(0.19)

0.0874

−0.58(0.23)

0.0117

−0.61(0.23)

0.0084

rs9877202

A/G

−0.05(0.04)

0.2295

−0.05(0.04)

0.1939

−0.05(0.05)

0.3580

−0.03(0.05)

0.5442

−0.07(0.05)

0.1939

−0.07(0.06)

0.1789

rs2036373

T/G

0.21(0.37)

0.5682

0.10(0.36)

0.7810

0.23(0.37)

0.5343

0.25(0.33)

0.4459

0.43(0.39)

0.2669

0.42(0.39)

0.2745

rs1501299

G/T

−0.14(0.05)

0.004

−0.15(0.05)

0.001

−0.13(0.06)

0.0258

−0.03(0.05)

0.510

−0.12(0.06)

0.0472

−0.12(0.06)

0.0468

rs3821799

T/C

0.03(0.03)

0.2802

0.03(0.03)

0.2768

0.02(0.03)

0.4649

0.02(0.03)

0.5966

0.02(0.04)

0.5226

0.03(0.04)

0.4464

rs9842733

A/T

−0.15(0.12)

0.2107

−0.10(0.12)

0.3741

0.05(0.14)

0.6928

0.02(0.14)

0.9038

−0.01(0.16)

0.9561

0.005(0.16)

0.9748

*N represents 52 missing values for adiponectin

Model 1: crude

Model 2: adjusted for age

§Model 3: adjusted for age, PEA

Model 4: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, blood glucose, HOMA-IR

Model 5: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, blood glucose, HOMA-IR, smoking status, physical activity score, BMI, alcohol consumption status

#Model 6: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, blood glucose, HOMA-IR, smoking status, physical activity score, BMI, alcohol consumption status, socioeconomic status (education level)

Two-tailed level of significance established as P ≤ 0.006

Table 5

Association between blood glucose and ADIPOQ SNPs among men and women in the Jackson Heart Study, N = 2,800*

Men, n = 1,071

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

0.01(0.02)

0.4877

0.02(0.02)

0.3755

0.03(0.02)

0.2168

0.01(0.02)

0.6174

0.004(0.02)

0.8347

0.005(0.02)

0.8140

rs12495941

G/T

0.03(0.05)

0.5088

0.04(0.04)

0.3695

0.03(0.06)

0.6776

−0.001(0.06)

0.9887

−0.02(0.07)

0.7920

−0.03(0.07)

0.6549

rs7627128

C/A

−0.05(0.07)

0.4997

−0.03(0.001)

0.7078

−0.01(0.09)

0.9074

0.02(0.09)

0.8449

0.03(0.09)

0.7506

0.04(0.09)

0.6765

rs9877202

A/G

−0.01(0.02)

0.7960

−0.01(0.02)

0.7940

−0.01(0.02)

0.6964

−0.004(0.02)

0.8658

−0.01(0.02)

0.6983

−0.01(0.02)

0.5648

rs2036373

T/G

−0.19(0.19)

0.3200

−0.20(0.18)

0.2764

−0.38(0.21)

0.0694

−0.38(0.20)

0.0489

−0.46(0.21)

0.0262

−0.45(0.20)

0.0289

rs1501299

G/T

−0.01(0.02)

0.6674

−0.01(0.02)

0.6454

−0.001(0.03)

0.9726

−0.01(0.02)

0.6306

−0.01(0.03)

0.6235

−0.01(0.03)

0.6798

rs3821799

T/C

0.005(0.01)

0.7486

0.002(0.01)

0.8970

0.0004(0.02)

0.9764

0.01(0.02)

0.6961

0.01(0.02)

0.6086

0.01(0.02)

0.6701

rs9842733

A/T

0.09(0.07)

0.2152

0.08(0.07)

0.2207

0.06(0.08)

0.4388

0.04(0.08)

0.6100

0.05(0.08)

0.5668

0.05(0.08)

0.5539

Women, n = 1,729

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

0.02(0.02)

0.1881

0.004(0.01)

0.1790

0.01(0.02)

0.3971

0.02(0.02)

0.1640

0.02(0.02)

0.2073

0.02(0.02)

0.1810

rs12495941

G/T

−0.003(0.03)

0.9296

0.01(0.03)

0.7260

0.04(0.04)

0.4129

0.02(0.04)

0.6438

0.01(0.04)

0.7305

0.01(0.04)

0.7427

rs7627128

C/A

−0.01(0.06)

0.8482

0.02(0.06)

0.7974

0.08(0.08)

0.2949

0.11(0.08)

0.1639

0.10(0.08)

0.2094

0.09(0.08)

0.2248

rs9877202

A/G

−0.03(0.02)

0.0672

−0.04(0.02)

0.0338

−0.01(0.02)

0.4711

−0.02(0.02)

0.2251

−0.02(0.02)

0.3394

−0.02(0.02)

0.3012

rs2036373

T/G

0.07(0.14)

0.6170

0.03(0.14)

0.8356

−0.01(0.14)

0.9198

0.01(0.13)

0.9309

−0.03(0.16)

0.8586

−0.03(0.16)

0.8422

rs1501299

G/T

0.02(0.02)

0.3343

0.02(0.02)

0.4112

0.002(0.02)

0.9379

−0.01(0.02)

0.5848

−0.01(0.02)

0.7571

−0.01(0.02)

0.7473

rs3821799

T/C

0.01(0.01)

0.4056

0.01(0.01)

0.4642

−0.003(0.01)

0.8430

0.01(0.01)

0.6920

0.01(0.01)

0.6938

0.01(0.01)

0.6240

rs9842733

A/T

0.02(0.05)

0.6652

0.03(0.05)

0.4631

0.02(0.05)

0.7694

0.04(0.05)

0.4431

0.02(0.05)

0.6909

0.03(0.05)

0.6373

*N represents 220 missing values for blood glucose

Model 1: crude

Model 2: adjusted for age

§Model 3: adjusted for age, PEA

Model 4: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin

Model 5: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, smoking status, physical activity score, BMI, alcohol consumption status

#Model 6: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin,, smoking status, physical activity score, BMI, alcohol consumption status, socioeconomic status (education level)

Two-tailed level of significance was established as P ≤ 0.006

Table 6

Association between HOMA-IR and ADIPOQ SNPs among men and women in the Jackson Heart Study, N = 2,347*

Men, n = 920

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

0.04(0.05)

0.3782

0.04(0.05)

0.3939

0.04(0.06)

0.4916

−0.03(0.05)

0.5570

−0.04(0.05)

0.4126

−0.05(0.05)

0.3641

rs12495941

G/T

0.43(0.14)

0.001

0.43(0.14)

0.002

0.76(0.18)

<.0001

0.41(0.15)

0.004

0.42(0.15)

0.005

0.40(0.15)

0.0086

rs7627128

C/A

−0.98(0.20)

<.0001

−0.99(0.20)

<.0001

−0.13(0.26)

<.0001

−0.78(0.20)

0.0001

−0.74(0.20)

0.0002

−0.73(0.20)

0.0003

rs9877202

A/G

−0.002(0.06)

0.9784

−0.001(0.06)

0.9913

−0.02(0.07)

0.7451

−0.03(0.05)

0.5270

−0.04(0.06)

0.4308

−0.05(0.06)

0.3797

rs2036373

T/G

0.42(0.51)

0.4158

0.42(0.51)

0.4102

0.06(0.63)

0.9262

−0.15(0.49)

0.7626

−0.05(0.52)

0.9197

−0.07(0.52)

0.8889

rs1501299

G/T

−0.05(0.06)

0.3976

−0.05(0.06)

0.3886

−0.03(0.07)

0.7110

−0.02(0.06)

0.7035

−0.04(0.06)

0.5522

−0.03(0.06)

0.6309

rs3821799

T/C

0.03(0.04)

0.4645

0.03(0.04)

0.4422

0.05(0.05)

0.2534

0.08(0.04)

0.0258

0.07(0.04)

0.0638

0.07(0.04)

0.0608

rs9842733

A/T

0.11(0.18)

0.5344

0.12(0.18)

0.5306

0.17(0.26)

0.4427

0.18(0.18)

0.3151

0.07(0.19)

0.6947

0.07(0.19)

0.6955

Women, n = 1,427

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β(SE)

P-value

β(SE)

P-value

β(SE)

P-value

β(SE)

P-value

β(SE)

P-value

β(SE)

P-value

rs16861205

G/A

0.07(0.04)

0.0795

0.07(0.04)

0.0776

0.06(0.04)

0.1816

0.07(0.04)

0.0491

0.07(0.04)

0.0594

0.07(0.04)

0.0624

rs12495941

G/T

0.11(0.08)

0.1814

0.12(0.08)

0.1510

0.11(0.11)

0.3332

0.01(0.10)

0.8898

0.01(0.10)

0.9282

0.004(0.10)

0.9626

rs7627128

C/A

−0.12(0.16)

0.4349

−0.11(0.16)

0.4908

0.001(0.21)

0.9959

0.08(0.17)

0.6421

0.05(0.17)

0.7616

0.05(0.17)

0.7874

rs9877202

A/G

−0.01(0.05)

0.8391

−0.01(0.05)

0.7704

0.05(0.05)

0.3250

0.01(0.04)

0.8426

0.01(0.05)

0.7866

0.01(0.05)

0.8183

rs2036373

T/G

−0.01(0.34)

0.9876

−0.02(0.34)

0.9438

−0.05(0.36)

0.8922

−0.002(0.3)

0.9933

−0.11(0.36)

0.7577

−0.10(0.36)

0.7696

rs1501299

G/T

0.15(0.05)

0.003

0.14(0.05)

0.003

0.13(0.06)

0.0226

0.06(0.05)

0.2300

0.08(0.05)

0.0996

0.08(0.05)

0.1006

rs3821799

T/C

0.01(0.03)

0.8004

0.01(0.03)

0.7921

−0.01(0.04)

0.7620

−0.02(0.03)

0.5097

−0.03(0.03)

0.3304

−0.03(0.03)

0.3290

rs9842733

A/T

0.30(0.16)

0.0176

0.31(0.13)

0.0139

0.29(0.15)

0.0539

0.33(0.13)

0.0098

0.27(0.13)

0.0385

0.28(0.13)

0.0337

*N represents 673 missing values for HOMA-IR

Model 1: crude

Model 2: adjusted for age

§Model 3: adjusted for age, PEA

Model 4: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin

Model 5: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, smoking status, physical activity score, BMI, alcohol consumption status

#Model 6: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, smoking status, physical activity score, BMI, alcohol consumption status, socioeconomic status (education level)

Two-tailed level of significance established as P ≤ 0.006

Table 7

Association between BMI and ADIPOQ SNPs among men and women in the Jackson Heart Study, N = 3,015*

Men, n = 1,150

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β(SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

0.02(0.01)

0.2907

0.01(0.01)

0.3250

0.02(0.02)

0.2014

0.001(0.01)

0.9212

0.001(0.01)

0.9286

−0.01(0.01)

0.9369

rs12495941

G/T

0.04(0.04)

0.3020

0.03(0.04)

0.3923

0.06(0.05)

0.2288

−0.02(0.04)

0.5470

−0.04(0.04)

0.3368

−0.04(0.04)

0.2705

rs7627128

C/A

−0.09(0.06)

0.1112

−0.10(0.06)

0.0656

−0.12(0.08)

0.1383

−0.01(0.05)

0.9122

−0.01(0.05)

0.9111

−0.002(0.05)

0.9631

rs9877202

A/G

0.01(0.02)

0.4062

0.01(0.02)

0.3984

0.002(0.02)

0.8888

−0.003(0.01)

0.8100

0.004(0.01)

0.7816

0.006(0.01)

0.7000

rs2036373

T/G

0.18(0.15)

0.2362

0.19(0.15)

0.2090

0.09(0.18)

0.6042

0.03(0.12)

0.8097

0.06(0.13)

0.6559

0.06(0.13)

0.6333

rs1501299

G/T

−0.01(0.02)

0.5381

−0.01(0.02)

0.5427

−0.02(0.02)

0.4453

−0.003(0.02)

0.8198

−0.01(0.02)

0.7433

−0.004(0.02)

0.7959

rs3821799

T/C

0.01(0.01)

0.5231

0.01(0.01)

0.4373

0.01(0.01)

0.4451

0.01(0.01)

0.3572

0.01(0.01)

0.2271

0.01(0.01)

0.3012

rs9842733

A/T

−0.05(0.06)

0.4189

−0.04(0.06)

0.4565

−0.03(0.07)

0.6265

0.01(0.05)

0.8381

0.02(0.05)

0.6911

0.01(0.05)

0.7695

Women, n = 1,865

SNPs

Alleles

Model 1

Model 2

Model 3§

Model 4

Model 5

Model 6#

  

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

β (SE)

P-value

rs16861205

G/A

0.01(0.01)

0.5560

0.01(0.01)

0.5908

0.02(0.02)

0.3135

0.01(0.01)

0.5001

0.002(0.01)

0.8239

0.004(0.01)

0.7495

rs12495941

G/T

0.06(0.03)

0.0447

0.05(0.03)

0.0724

0.05(0.04)

0.2977

0.01(0.03)

0.7523

0.01(0.03)

0.6878

0.01(0.03)

0.7813

rs7627128

C/A

0.001(0.05)

0.9921

−0.01(0.05)

0.8213

0.06(0.07)

0.4078

0.09(0.06)

0.1436

0.09(0.06)

0.1172

0.09(0.06)

0.1307

rs9877202

A/G

−0.01(0.02)

0.7077

−0.01(0.02)

0.7377

0.002(0.02)

0.9166

−0.01(0.01)

0.3950

−0.01(0.02)

0.5705

−0.01(0.02)

0.5568

rs2036373

T/G

−0.07(0.13)

0.5655

−0.05(0.13)

0.6915

−0.05(0.14)

0.6920

−0.05(0.11)

0.6477

−0.02(0.12)

0.8414

−0.03(0.12)

0.7874

rs1501299

G/T

0.01(0.02)

0.7208

0.01(0.02)

0.6198

0.01(0.02)

0.5665

−0.01(0.02)

0.4194

−0.02(0.02)

0.3642

−0.02(0.02)

0.3543

rs3821799

T/C

0.002(0.01)

0.8623

0.002(0.01)

0.8598

0.005(0.01)

0.7169

−0.0001(0.01)

0.9897

0.003(0.01)

0.7858

0.004(0.01)

0.7302

rs9842733

A/T

0.03(0.04)

0.4526

0.02(0.04)

0.5909

0.07(0.05)

0.1991

0.06(0.04)

0.1338

0.06(0.04)

0.1485

0.06(0.04)

0.1391

*N represents 5 missing values for BMI

Model 1: crude

Model 2: adjusted for age

§Model 3: adjusted for age, PEA

Model 4: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma peptin

Model 5: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, smoking status, physical activity score, alcohol consumption status

#Model 6: adjusted for age, PEA, LDL, HDL, triglyceride, CRP, plasma leptin, smoking status, physical activity score, alcohol consumption status, socioeconomic status (education level)

Two-tailed level of significance established as P ≤ 0.006

Association between haplotypes with HOMA-IR and adiponectin

SNPs that were significantly associated with HOMA-IR and adiponectin (rs7627128 and rs16861205) were tested. The haplotype analysis did not reveal any significant association after controlling for covariates (data not shown).

Discussion

Selected ADIPOQ SNPs were analyzed to assess their association with type 2 diabetes and related phenotypes in a large well characterized sample of African Americans. Our findings show the ADIPOQ variant rs16861205 (MAF = 0.21) was significantly associated with a lower level of plasma adiponectin in women with minor allele A than none-carriers. This association was attenuated after adjusting for PEA and biological risk factors but persisted when fully adjusted for age, PEA, biological and behavioral risk factors and SES. These findings suggest an etiological association between genetic variant rs16861205 and lower levels of adiponectin observed in African American women either directly or through another variant that is linked to it. Gender can be considered a measured environmental risk factor which incorporates established anatomical, physiological, and behavioral differences between genders. The gender dismorphism in adiponectin levels is well established starting at puberty - possibly influenced by sex hormones which might explain our observation of lower adiponectin in women [32]. Our findings of observed lower levels of adiponectin in women are consistent with other research that similarly document lower levels of adiponectin in African American women when compared to other race/ethnic women [32, 36]. Cohen et al., for instance, observed a lower level of serum adiponectin in African American women when compared to white women [36]. However, unlike our finding, they did not find any associations between adiponectin and the SNPs in the adiponectin gene that were assessed. This observation may be due to a smaller sample size. ADIPOQ variant rs1501299 in women with minor allele T also had lower plasma adiponectin after adjusting for age, but this association disappeared after adjusting for PEA, biological and behavioral risk factors and SES.

Our findings also revealed that the ADIPOQ SNP rs12495941 (MAF = 0.35) was significantly associated with higher HOMA-IR among men with carriers of the minor allele T suggesting perhaps a relationship between the variant and likelihood of type 2 diabetes. The rs1249541variant is located in the intron 1 region not involved in any putative transcription factor binding site which means this SNP is a noncoding variant without obvious regulatory function. Thus, this SNP may be in linkage disequilibrium with another functional variant in African Americans [15]. We attempted to predict in sylico the potential functionality of the tagged SNPS with software AliBaba in order to test their role as potential transcriptional regulators of adiponectin expression through different mechanisms such as sequence alterations involved splicing processes and modifications in transcriptional factors binding motifs [37]. Our analysis revealed the tested SNPs disrupted or resulted in the appearance of putative transcription factor binding sites. Further functional analysis studies of this and other SNPs, particularly in African Americans, are needed to elucidate the potential role in regulating adiponectin expression.

ADIPOQ SNP rs1249541 has been found to be associated with adiponectin levels and anthropomorphic measures in other populations [38]. However, to the best of our knowledge, this is the first report on a gender specific association between the rs12495941 variant and HOMA-IR. The Bonferroni significance threshold, however, was lost in the model that was fully adjusted for SES. On the other hand, the ADIPOQ SNP rs7627128 was also associated with HOMA-IR in male carriers of the minor allele who had significantly lower HOMA-IR, and this finding was consistent in each of the models. As with rs1249541, this SNP is located in the intron 1 region and lacks obvious regulatory function and also represents a novel finding. ADIPOQ SNP rs1501299 in women with minor allele T had higher HOMA-IR but this association did not persist beyond adjustment for age. This attenuation underscores the importance of including adjustment for African ancestry (model 3) in analyses of African American populations. The association at different SNPs in our sample is not unexpected. Ukkola et al. indicate this may be a reflection of ethnic differences in adiponectin gene structure based on their evaluation of African Americans from the HERITAGE study [38]. The data in their study are further supported by evidence demonstrating African Americans have reduced plasma adiponectin concentrations when compared to other ethnic groups [10]. The potential for ethnic differences in the adiponectin gene emphasizes the need to study genetic associations in a variety of populations. The differential sex observation related to SNPs rs12495941 and rs7627128 is not clearly understood, but may be related to sex-specific hormones such as estradiol and testosterone as observed with rs16861205 and adiponectin [3941]. There was substantial missing HOMA-IR data in our data which may likewise result in biased findings. Further research on ADIPOQ variants and HOMA-IR on both sexes accounting for sex hormones is warranted to elucidate the biological mechanisms of this association.

Our study did not reveal any association of ADIPOQ SNPs with type 2 diabetes, blood glucose or BMI in men or women. These findings are interesting given prior evidence documenting the association of ADIPOQ gene with type 2 diabetes, insulin resistance, elevated blood glucose and BMI [1215]. However, such reports did not adequately control for ancestry, biological and behavioral risk factors or SES when assessing the association of ADIPOQ polymorphisms. An investigation by Bostrom et al., for instance, similarly found that SNP rs3821799 in the ADIPOQ gene was not associated with type 2 diabetes in African Americans [15]. These investigators also tested the association of SNP rs1501299 and found no association with type 2 diabetes. Previous studies that did not include African Americans detected an association of ADIPOQ SNPs in the promoter region or in exons (exon 3) with morbid obesity and with type 2 diabetes [42, 43]. Our analysis of variant rs12495941 revealed no associations with our outcomes. A study of this variant in a sample of Indians also found no association with type 2 diabetes or insulin sensitivity related variables [44]. This polymorphism was, however, associated with fasting glucose levels in Hispanics [45]. We also assessed variant rs9877202. Few studies have investigated this intronic polymorphism. However, this variant was not associated with any study outcomes [46]. A recent meta-analysis reported a genetic susceptibility for type 2 diabetes linked to rs1501299 in East Asian populations [47]. We found no association with any of the outcomes in our study.

Several studies have reported a significant association between BMI and various ADIPOQ SNPs [17, 36, 38], albeit with inconsistent results across studies. Furthermore, such studies were conducted in non-African American populations and did not report sex differences. However, evidence from a genome wide association study by Liu et al. identified two waist-related genetic loci (LHX2 and RREB1) associated with fat distribution in African American populations [17]. A report by An et al. of the IRAS Family Study, on the other hand, indicates no association between selected ADIPOQ SNPs and BMI in African Americans [42]. They further report that only one promoter SNP was positively associated with plasma adiponectin and fasting glucose in African Americans – rs17300539.

Strengths and limitations

The main strength of this investigation is that findings were from the largest community-based sample of African Americans, a cohort with strict protocol and high quality-control. It also addresses a health outcome that disproportionately affects African Americans. In addition, it presents differential findings between African American men and women. Further, the sample size far exceeds those in previous reports and the study used a tag SNP approach that captures much of the variation across the adiponectin gene in African Americans. The analysis was also adjusted for global/aggregate genetic ancestry, biological and behavioral risk factors and socioeconomic status. In terms of limitations, findings cannot be generalized to other ethnic groups. Secondly, this is a cross-sectional analysis and causality between ADIPOQ SNPs and phenotypes cannot be attributed without longitudinal tracking or incidence. Finally, although some of the associated SNPs did not reach a Bonferroni-adjusted threshold of significance, it will be important to replicate these findings in additional suitable cohorts.

Conclusion

The objective of this study was to assess the association of tag ADIPOQ SNPs with type 2 diabetes and related phenotypes between African American men and women. No association was observed between ADIPOQ SNPs and type 2 diabetes, blood glucose or BMI in men or women. A significant association with variant rs16861205 and lower adiponectin level was revealed in women with minor allele A. Variant rs12495941 revealed men with minor allele T had higher HOMA-IR but significance disappeared after adjustment for SES. Variant rs7627128 indicated men with minor allele A had significantly lower HOMA-IR that remained consistent in the fully adjusted model. These associations represent novel findings. As with any gene-phenotype association study, it is necessary to replicate study findings in other large well characterized study populations. Our well-adjusted findings nevertheless suggest important new insights regarding the association between ADIPOQ SNPs and type 2 diabetes and related phenotypes in African American men and women a disproportionately affected population.

Availability of supporting data

Data for this study were deposited in the National Institutes of Health The database of Genotypes and Phenotypes (DbGAP) found at www.ncbi.nlm.gov/gap/?item=Jackson+Heart+Study [48].

Declarations

Acknowledgments

The authors thank the participants in the Jackson Heart Study for their long-term commitment and important contributions to the study. Funding for the Jackson Heart Study was supported by contracts HHSN268201300046C, HHSN26820130047C, HHSN26820130048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung and Blood Institute and the National Institute on Minority Health and Health Disparities. The measurement of adiponectin was partially supported by PHS Award UL1 RR025008 from the National Center for Research Resources and by UH1 HL073461 from the National Heart, Lung and Blood Institute. Sharon K. Davis, Samson Y. Gebreab, Ruihua Xu, Pia Riestra, Rumana J. Khan and Amadou Gaye are supported by the intramural program of the National Human Genome Research Institute.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Human Genome Research Institute, Genomics of Metabolic, Cardiovascular and Inflammatory Disease Branch, Social Epidemiology Research Unit
(2)
Department of Physiology, University of Mississippi Center
(3)
Indiana University Bloomington, School of Public Health

References

  1. National Center for Health Statistics. Health, United States, 2011: with special features on socioeconomic status and health. Department of Health and Human Services. Hyattsville, MD 2012.Google Scholar
  2. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med. 1991;151:1359–64.PubMedView ArticleGoogle Scholar
  3. Bryne C, Nedelman J, Luke RG. Race, socioeconomic status, and the development of end-stage renal disease. Am J Kidney Dis. 1994;23:16–22.View ArticleGoogle Scholar
  4. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and White adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253–9.PubMedView ArticleGoogle Scholar
  5. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011;154:303–9.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Kasim-Karakass SE. Ethnic differences in the insulin resistance syndrome. Am J Clin Natr. 2000;71:670–1.Google Scholar
  7. Sudano JJ, Baker DW. Explaining US racial/ethnic disparities in health declines and mortality in late middle age: the role of socioeconomic status in health behaviors and health insurance. Soc Sci Med. 2006;62:909–22.PubMedView ArticleGoogle Scholar
  8. Sonnenberg GE, Krakower GR, Kissenbah AH. A novel pathway to the manifestation of metabolic syndrome. Obes Res. 2004;12:180–6.PubMedView ArticleGoogle Scholar
  9. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005;5:129–34.PubMedView ArticleGoogle Scholar
  10. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism. 2004;53:1–3.PubMedView ArticleGoogle Scholar
  11. Heid IM, Henneman P, Hicks A, Coassin S, Winkler T, Aulchenko YS, et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 43659 European individuals. Atherosclerosis. 2010;208:412–20.PubMedPubMed CentralView ArticleGoogle Scholar
  12. Mackevics V, Heid IM, Wagner SA, Cip P, Doppelmayr H, Lejnieks A, et al. The adiponectin gene is associated with adiponectin levels but not with characteristics of the insulin resistance syndrome in health Caucasians. Eur Jo Hum Gen. 2006;14:349–56.View ArticleGoogle Scholar
  13. Dolley G, Bertrais S, Frochot V, Bebel JF, Guerre-Millo M, Tores F, et al. Promoter adiponectin polymorphisms and waist/hip ratio variation in a prospective French adult study. In Jou Obesity. 2008;32:669–75.View ArticleGoogle Scholar
  14. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, et al. Single-nucleotide polymorphism haplotypes in both proximal promoter and exon 3 of the APM 1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genetics. 2002;11:2607–14.View ArticleGoogle Scholar
  15. Bostrom MA, Freedman BI, Langefeld CD, Liu L, Hicks PJ, Bowden DW. Association of adiponectin gene polymorphisms with type 2 diabetes an African American population enriched for nephropathy. Diabetes. 2009;58:499–504.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Chen G, Bentley A, Adeyemo A, Shriner D, Zhou J, Doumatey A, et al. Genome-wide association study identifies novel loci association with fasting insulin and insulin resistance in African Americans. Hum Mol Genetics. 2012;20:4530–6.View ArticleGoogle Scholar
  17. Liu C-T, Monda KL, Taylor KC, Lange L, Demerath EW, Palmas W, et al. Genome-wide association of body fat distribution in African ancestry populations suggests new loci. PLoS Genet. 2013;8, e1003681.View ArticleGoogle Scholar
  18. Speechia C, Scott K, Fortina P, Devoto M, Falkner B. Association of a polymorphic variant of the adiponectin gene with insulin resistance in African Americans. Clin Transl Sci. 2008; 3194–3199Google Scholar
  19. Ng MC, Shriner D, Chen BH, Li J, Chen W-M, Guo X, et al. Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes. PLoS Genet. 2014;10:e1004517.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Taylor Jr HA. The Jackson Heart Study; an overview. Ethn Dis. 2005;15:1–3.Google Scholar
  21. Carpenter MA, Evans G, Skelton T, Jensen R, Sarpong D. Laboratory, reading center, and coordinating center data management in the Jackson Heart Study. Am J Med Sci. 2004;328i:131–44.View ArticleGoogle Scholar
  22. Musunuru K, Lettre G, Young T, Farlow DN, Pirruccello JP, Ejebe KG, et al. NHLBI candidate gene association resource. Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet. 2010;3:267–75.PubMedPubMed CentralView ArticleGoogle Scholar
  23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62–9.PubMed CentralView ArticleGoogle Scholar
  24. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma adiponectin. Clin Chem Lab Med. 2006;10:1264–8.Google Scholar
  25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatsis model assessment: insulin resistance and beta-cell function form fasting plasma glucose and insulin concentration in men. Diabetologia. 1985;28:412–9.PubMedView ArticleGoogle Scholar
  26. Release #24; http://www.hapmap.org
  27. deBakker PI, Ferreira MA, Jia X, Neale BM, Raychaudhuri S, Voight BF. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum Mol Genetics. 2008;17:R122–8.View ArticleGoogle Scholar
  28. Duan Q, Liu EY, Auer PL, Zhang G, Lange EM, Jun G, et al. Imputation of coding variants in African Americans: better performance using data from the exome sequencing project. Bioinformatics. 2013;29:2744–9.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Price AL, Tandon A, Patterson N, Barnes KC, Rafaels N, Ruczinski I, et al. Sensitive detection of chromosomal segments of distinct ancestry in admixed populations. PLoS Genet. 2009;5, e1000519.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Pattererson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, et al. Methods for high-density admixture mapping of disease genes. Am Jou Hum Genetics. 2004;74:979–1000.View ArticleGoogle Scholar
  31. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, et al. Concept, design and implementation of a cardiovascular gene-centric 50k SNP array for large-scale genome association studies. PLoS One. 2008;10, e3583.View ArticleGoogle Scholar
  32. Bidulescu A, Liu J, Chen Z, Hickson DA, Musani SK, Samdarshi TE, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson Heart Study. Fron Pub Health. 2013. doi:10.3389/fpubh.2013.00016.Google Scholar
  33. Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW, Taylor HA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol. 2009;72:32–7.View ArticleGoogle Scholar
  34. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Gen & Inform. 2012;10:117–22.View ArticleGoogle Scholar
  35. SAS Institutes Inc, Cary North Carolina.Google Scholar
  36. Cohen EM, Williams SM, Zheng W, Cai Q, Long J, Smith JR. ADIPOQ, ADIPOR1, and ADIPOR2 polymorphisms in relation to serum adiponectin levels and body mass index in black and white women. Obesity. 2011;19:2053–62.PubMedPubMed CentralView ArticleGoogle Scholar
  37. Grabe N. AliBaba2;context specific identification of transcription factor binding sites. In Silico Biology. 2002;2(1):S1–15.PubMedGoogle Scholar
  38. Ukkola O, Santaniemi M, Rankien T, Leon AS, Skinner JS, Wilmore JH, et al. Adiponectin polymorphisms, adiposity and insulin metabolism: HERITAGE family study and Oulu diabetic study. Ann Med. 2005;37:141–50.PubMedView ArticleGoogle Scholar
  39. Combs TP, Berg AH, Rajala MW, Klebanovs IP, Jimenez-Chillaron JC, Patti ME, et al. Sexual differentiation, pregnancy, caloric restriction and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003;52:267–76.View ArticleGoogle Scholar
  40. Nishizawa H, Shimomura I, Skisida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin on insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51:2734–41.PubMedView ArticleGoogle Scholar
  41. Xu A, Chan KW, Hoo RL, Wang Y, Tan KC, Zhang J, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–80.PubMedView ArticleGoogle Scholar
  42. Vasseur F, Helbecque N, Lobbens S, Vassueur-Delannoy V, Dina C, Clement K, et al. Hypoadipoectinamia (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia. 2005;48:892–9.PubMedView ArticleGoogle Scholar
  43. Schwarz PE, Govindarajalu S, Towers W, Schwanebeck U, Fisher S, Vasseur F, et al. Haplotypes in the promoter region of the ADIPOQ gene as associated with increased diabetes risk in a German Caucasian population. Horm Metab Res. 2006;38:447–51.PubMedView ArticleGoogle Scholar
  44. Wassel CL, Pankow JS, Rasmussen-Torvik L, Li N, Taylor KD, Guo X, et al. Association of SNPS in ADIPOQ and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis (MESA). Obesity. 2011;10(10):2053–62.Google Scholar
  45. An SS, Hanley AJG, Ziegler JT, Brown WM, Haffner SM, Norris JM, et al. Association between ADIPOQ SNPs with plasma adiponectin and glucose homeostatsis and adiposity phenotypes in the IRAS Family Study. Mol Genetics Metab. 2012;107:721–8.View ArticleGoogle Scholar
  46. Riestra P, Gebreab SY, Khan RJ, Bidulescu A, Correa A, Tekola-Ayele F, et al. Gender specific associations between ADIPOQ gene polymorphisms and adiponectin levels and obesity in the Jackson Heart Study. BMC Med Gen. 2015;10:65. doi:10.1186/s12881-015-214-x.View ArticleGoogle Scholar
  47. Tu Y, Yu Q, Fan G, Yang P, Lai Q, Yang F, et al. Assessment of type 2 diabetes risk conferred by SNPs rs2241766 and rs1501299 in the ADIPOQ gene, a case/control study combined with meta-analysis. Mol and cell endo. 2014;396(1–2):1–9.View ArticleGoogle Scholar
  48. dbGAP DOI link www.ncbi.nlm.gov/gap/?item=Jackson+Heart+Study

Copyright

© Davis et al. 2015

Advertisement